Agendia Gets European Rights to Arcturus TUO-gene Profile

genomeweb
360dx

Agendia Gets European Rights to Arcturus TUO-gene Profile

Feb 02, 2005

NEW YORK, Feb. 2 (GenomeWeb News) - Agendia, a Dutch firm that specializes in gene-expression services, has signed an agreement with Arcturus Bioscience to license the company's exclusive European rights to its Tumor of Unknown Origin(TUO)-gene expression profile, the companies said today.

To read the full story....

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

Exact Sciences Q1 Revenues Up 87 Percent
Broad Researchers Develop Protocol to Use CRISPR-Based Diagnostic Tool for Zika Testing
CRISPR Company Cofounded by Jennifer Doudna Comes Out of Stealth Mode
Single-Cell Transcriptomes Reveal Cell Differentiation Dynamics in Zebrafish, Frog Embyogenesis
ABRF Speakers Outline Disaster Prep for Core Facilities
Rainbow Genomics, UCLA Partner to Offer Exome Dx in Asia

The Scan

Getting It Early

Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.

Food Bugs to Meet Sequencers

The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.

From Ancient Bathrooms

Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.

This Week in Nature

In Nature this week: ash dieback disease fungal genome, and more.

Main menu